KR20230104782A - Bcr-abl 티로신 키나제 억제용 7-아자인돌 화합물 - Google Patents

Bcr-abl 티로신 키나제 억제용 7-아자인돌 화합물 Download PDF

Info

Publication number
KR20230104782A
KR20230104782A KR1020237015285A KR20237015285A KR20230104782A KR 20230104782 A KR20230104782 A KR 20230104782A KR 1020237015285 A KR1020237015285 A KR 1020237015285A KR 20237015285 A KR20237015285 A KR 20237015285A KR 20230104782 A KR20230104782 A KR 20230104782A
Authority
KR
South Korea
Prior art keywords
alkylene
alkyl
independently
cycloalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237015285A
Other languages
English (en)
Korean (ko)
Inventor
조셉 피. 리시카토스
사무엘 킨츠
리 렌
Original Assignee
인라이븐 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인라이븐 테라퓨틱스, 인크. filed Critical 인라이븐 테라퓨틱스, 인크.
Publication of KR20230104782A publication Critical patent/KR20230104782A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237015285A 2020-10-05 2021-10-04 Bcr-abl 티로신 키나제 억제용 7-아자인돌 화합물 Pending KR20230104782A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063087780P 2020-10-05 2020-10-05
US63/087,780 2020-10-05
PCT/US2021/071692 WO2022076973A1 (en) 2020-10-05 2021-10-04 7-azaindole compounds for inhibition of bcr-abl tyrosine kinases

Publications (1)

Publication Number Publication Date
KR20230104782A true KR20230104782A (ko) 2023-07-10

Family

ID=81125544

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237015285A Pending KR20230104782A (ko) 2020-10-05 2021-10-04 Bcr-abl 티로신 키나제 억제용 7-아자인돌 화합물

Country Status (8)

Country Link
US (1) US20240043420A1 (enExample)
EP (1) EP4225741A4 (enExample)
JP (1) JP7826325B2 (enExample)
KR (1) KR20230104782A (enExample)
CN (1) CN116438182A (enExample)
IL (1) IL301740A (enExample)
MX (1) MX2023003996A (enExample)
WO (1) WO2022076973A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3196620A1 (en) 2020-10-05 2022-04-14 Enliven Therapeutics, Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
WO2023081637A1 (en) * 2021-11-02 2023-05-11 Enliven Therapeutics, Inc. Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
CN116063212B (zh) * 2023-01-28 2023-06-27 山东国邦药业有限公司 一种4-苯硫基-1,2-苯二胺的制备方法
CN119954701B (zh) * 2024-06-18 2026-06-16 青岛润农化工有限公司 一种丁醚脲的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
JP5122280B2 (ja) 2004-06-30 2013-01-16 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼのインヒビターとして有用なアザインドール
EP2325184A1 (en) * 2004-06-30 2011-05-25 Vertex Pharmceuticals Incorporated Azaindoles useful as inhibitors of protein kinases
NZ553267A (en) 2004-07-27 2010-09-30 Sgx Pharmaceuticals Inc Pyrrolo-pyridine kinase modulators
US8604055B2 (en) * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
JP2007099640A (ja) 2005-09-30 2007-04-19 Tsumura & Co 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
FR2941948B1 (fr) * 2009-02-12 2013-04-05 Nova Decision Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src
FR3000492B1 (fr) * 2012-12-28 2015-09-11 Oribase Pharma Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
US10696687B2 (en) * 2015-08-20 2020-06-30 Changzhou Jiekai Pharmatech Co., Ltd. Pyrazolo fused heterocyclic compounds as ERK inhibitors

Also Published As

Publication number Publication date
CN116438182A (zh) 2023-07-14
WO2022076973A1 (en) 2022-04-14
US20240043420A1 (en) 2024-02-08
IL301740A (en) 2023-05-01
EP4225741A4 (en) 2024-10-30
EP4225741A1 (en) 2023-08-16
JP7826325B2 (ja) 2026-03-09
JP2023545219A (ja) 2023-10-26
MX2023003996A (es) 2023-06-15

Similar Documents

Publication Publication Date Title
CN112778276B (zh) 作为shp2抑制剂的化合物及其应用
JP7826325B2 (ja) Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための７－アザインドール化合物
JP2018150358A (ja) Ｔａｎｋ結合キナーゼインヒビター化合物
KR102912146B1 (ko) 시클로알칸-1,3-디아민 유도체
US11345681B1 (en) Inhibitors of fibroblast growth factor receptor kinases
US20170107204A1 (en) Trka kinase inhibitors, compositions and methods thereof
CN121013849A (zh) 作为wrn抑制剂的杂环化合物
CN119019388B (zh) 用于抑制Bcr-Abl酪氨酸激酶的5-和6-氮杂吲哚化合物
CA3231988A1 (en) Azaindazole macrocycle compound and use thereof
AU2019363657B2 (en) 5-azaindazole derivatives as adenosine receptor antagonists
TW202214634A (zh) 雜環化合物及其衍生物
WO2023239846A1 (en) Heterocyclic compounds as pi3kα inhibitors
CN116648453A (zh) 用于抑制Bcr-Abl酪氨酸激酶的5-和6-氮杂吲哚化合物
EP4377304A1 (en) Srpk inhibitors
CA3213823A1 (en) Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
RU2793247C2 (ru) Циклоалкан-1,3-диаминовое производное
CN120129682A (zh) 用于抑制raf激酶的萘啶化合物
BR112020019595B1 (pt) Composto heterocíclico inibidor da quinase 12 dependente de ciclina (cdk12), e, medicamento o compreendendo

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902